SCHEMBL4420135

SCHEMBL4420135

COC(=O)c1cc(C(N)=O)c(N)cc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.56
GAA P10253 6/20 0.54
ALDH1A1 P00352 5/20 0.50
HSD17B10 Q99714 3/20 0.50
MAPT P10636 2/20 0.50
HPGD P15428 2/20 0.50
GLA P06280 2/20 0.50
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50
ATM Q13315 1/20 0.50
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA7 P43166 2/20 0.49
CA9 Q16790 2/20 0.49
CA14 Q9ULX7 2/20 0.49
ABL1 P00519 1/20 0.49
PDK2 Q15119 1/20 0.49
PDK4 Q16654 1/20 0.49
TSHR P16473 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2701033 0.85 GAA (0.61) KDM4EGAAALDH1A1HSD17B10MAPT
SCHEMBL10887141 0.84 KDM4E (0.58) KDM4EGAAALDH1A1HSD17B10MAPT
SCHEMBL5692887 0.82 KDM4E (0.70) KDM4EGAAALDH1A1HSD17B10MAPT
SCHEMBL4758833 0.80 KDM4E (0.73) KDM4EGAAALDH1A1HSD17B10MAPT
SCHEMBL1538335 0.80 CA12 (0.63) KDM4EGAAALDH1A1HSD17B10MAPT
SCHEMBL18863815 0.79 GAA (0.59) KDM4EGAAALDH1A1HSD17B10MAPT
SCHEMBL29370673 0.79 GAA (0.59) KDM4EGAAALDH1A1HSD17B10MAPT
SCHEMBL2721466 0.79 KDM4E (0.56) KDM4EGAAALDH1A1HSD17B10MAPT
SCHEMBL2427397 0.79 KDM4E (0.54) KDM4EGAAALDH1A1HSD17B10MAPT
SCHEMBL31738319 0.79 KDM4E (0.71) KDM4EGAAALDH1A1HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7498335-B2 Method of producing an antiangiogenic or vascular permeability reducing effect ASTRAZENECA AB (CH) 2009-03-03 US disclosed
EP-1218353-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA UK LTD (GB) 2007-10-17 EP disclosed
EP-1272185-B1 USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2005-07-27 EP disclosed
US-6806274-B1 IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS ASTRAZENECA UK LIMITED (GB) 2004-10-19 US disclosed
EP-1272185-A2 USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2003-01-08 EP disclosed
EP-1218353-A1 QUINAZOLINE DERIVATIVES AstraZeneca UK Limited (GB) 2002-07-03 EP disclosed
WO-2002002534-A1 QUINAZOLINES WITH THERAPEUTIC USE ASTRAZENECA AB (SE) 2002-01-10 WO disclosed
WO-2001066099-A2 USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2001-09-13 WO disclosed
WO-2001004102-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA UK LIMITED (GB) 2001-01-18 WO disclosed